Skip Navigation
American College of Physicians Logo
  • Subscribe
  • Submit a Manuscript
  • Sign In
    Sign in below to access your subscription for full content
    INDIVIDUAL SIGN IN
    Sign In|Set Up Account
    You will be directed to acponline.org to register and create your Annals account
    INSTITUTIONAL SIGN IN
    Open Athens|Shibboleth|Log In
    Annals of Internal Medicine
    SUBSCRIBE
    Subscribe to Annals of Internal Medicine.
    You will be directed to acponline.org to complete your purchase.
Annals of Internal Medicine Logo Menu
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives
  • Author Info
Advanced Search
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Summaries for Patients |20 June 2006

Abatacept for People with Active Rheumatoid Arthritis Free

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
  • The summary below is from the full report titled “Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis. A Randomized Trial.” It is in the 20 June 2006 issue of Annals of Internal Medicine (volume 144, pages 865-876). The authors are J.M. Kremer, H.K. Genant, L.W. Moreland, A.S. Russell, P. Emery, C. Abud-Mendoza, J. Szechinski, T. Li, Z. Ge, J.-C. Becker, and R. Westhovens.


Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
×
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Jump To
  • Full Article
  • FULL ARTICLE
    • What is the problem and what is known about it so far?
    • Why did the researchers do this particular study?
    • Who was studied?
    • How was the study done?
    • What did the researchers find?
    • What were the limitations of the study?
    • What are the implications of the study?
  • Figures
  • Tables
  • Supplements
  • Audio/Video
  • Summary for Patients
  • Clinical Slide Sets
  • CME / MOC
  • Comments
  • Twitter Link
  • Facebook Link
  • Email Link
More
  • LinkedIn Link
  • CiteULike Link

What is the problem and what is known about it so far?

Rheumatoid arthritis is joint pain and stiffness caused by an immune reaction to joint tissue linings. It damages the joints and can even destroy them. Rheumatoid arthritis usually affects the hands, feet, knees, shoulders, and wrists, but it can develop in any joint. There is no cure, but treatment improves signs and symptoms and slows joint damage. Treatment is with drugs that alter the body's immune reactions. Abatacept is a new drug that targets specific components of the immune system. Abatacept inhibits the specific immune cells that cause rheumatoid arthritis and has been shown to improve symptoms in people with rheumatoid arthritis. It has not been directly compared with drugs that are commonly used to treat rheumatoid arthritis, such as methotrexate.

Why did the researchers do this particular study?

To compare the ability of abatacept and methotrexate to improve symptoms and slow joint damage in people with rheumatoid arthritis.

Who was studied?

652 adults with painful rheumatoid arthritis despite taking methotrexate for at least 3 months.

How was the study done?

The researchers assessed participants' symptoms and signs, ability to perform everyday activities, and quality of life before starting the study. They also looked at disease activity by measuring joint damage in x-rays. The researchers then randomly assigned participants to receive abatacept or placebo for 1 year. Abatacept was given intravenously twice in the first month, then once a month for 11 more months. Participants in both groups continued taking methotrexate. The researchers repeated their measurements every month to assess improvement.

What did the researchers find?

Participants taking abatacept improved more in all measures than participants taking placebo. Their symptoms and signs, everyday activities, and quality of life improved. Joint damage also progressed at half the rate. Participants in the 2 groups experienced similar adverse events. More participants taking abatacept experienced side effects, and they tended to develop infections more often. However, more participants taking placebo left the study prematurely because their symptoms and signs of rheumatoid arthritis did not improve.

What were the limitations of the study?

The study included participants who had had rheumatoid arthritis for more than a year and whose condition had not improved with methotrexate treatment. The findings may not apply to people with newer disease or to those who responded to methotrexate. The study lasted only a year. The benefits and risks of abatacept for longer periods require study.

What are the implications of the study?

Abatacept seems to be safe and effective for people with rheumatoid arthritis who do not respond to methotrexate treatment. The benefits and risks of taking abatacept for more than a year require more study. The role of the drug for different people at different stages of rheumatoid arthritis and its benefits and risks compared with other rheumatoid arthritis drugs also require further study.

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

This feature is available only to Registered Users

Subscribe/Learn More
Submit a Comment

0 Comments

PDF
Not Available
Citations
Citation

Abatacept for People with Active Rheumatoid Arthritis. Ann Intern Med. 2006;144:I–18. doi: 10.7326/0003-4819-144-12-200606200-00001

Download citation file:

  • RIS (Zotero)
  • EndNote
  • BibTex
  • Medlars
  • ProCite
  • RefWorks
  • Reference Manager

© 2018

×
Permissions

Published: Ann Intern Med. 2006;144(12):I-18.

DOI: 10.7326/0003-4819-144-12-200606200-00001

©
2006 American College of Physicians
0 Citations

See Also

Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis: A Randomized Trial
View MoreView Less

Related Articles

Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis: A Randomized Trial
Annals of Internal Medicine; 144 (12): 865-876
Abatacept in Rheumatoid Arthritis: A New Branch on the “Biologics” Tree
Annals of Internal Medicine; 144 (12): 933-935
Update in Rheumatology
Annals of Internal Medicine; 145 (11): 834-838
In patients with rheumatoid arthritis, bDMARD therapy was not associated with malignant neoplasms
Annals of Internal Medicine; 168 (4): JC23
View MoreView Less

Journal Club

In patients with rheumatoid arthritis, bDMARD therapy was not associated with malignant neoplasms
Annals of Internal Medicine; 168 (4): JC23
Patients with new-onset rheumatoid arthritis had increased risk for ischemic and nonischemic heart failure
Annals of Internal Medicine; 167 (2): JC8
Review: In rheumatoid arthritis, TNF-α inhibitors do not differ from placebo or DMARDs for all-cause mortality
Annals of Internal Medicine; 164 (4): JC20
Review: In rheumatoid arthritis, adding rituximab to methotrexate improves clinical outcomes
Annals of Internal Medicine; 162 (12): JC9
View MoreView Less

Related Point of Care

Rheumatoid Arthritis
Annals of Internal Medicine; 153 (1): ITC1-1
View MoreView Less

Related Topics

Rheumatoid Arthritis
Rheumatology

Rheumatoid Arthritis, Rheumatology.

PubMed Articles

Rutin and rutin-conjugated gold nanoparticles ameliorate collagen-induced arthritis in rats through inhibition of NF-?B and iNOS activation.
Int Immunopharmacol 2018;
Hot joints: myth or reality? A thermographic joint assessment of inflammatory arthritis patients.
Clin Rheumatol 2018.
View More

Results provided by: PubMed

CME/MOC Activity Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
The Comments Feature Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
link to top

Content

  • Home
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives

Information For

  • Author Info
  • Reviewers
  • Press
  • Readers
  • Institutions / Libraries / Agencies
  • Advertisers

Services

  • Subscribe
  • Renew
  • Alerts
  • Current Issue RSS
  • Online First RSS
  • In the Clinic RSS
  • Reprints & Permissions
  • Contact Us
  • Help
  • About Annals
  • About Mobile
  • Patient Information
  • Teaching Tools
  • Annals in the News
  • Share Your Feedback

Awards

  • Personae Photography Prize
  • Junior Investigator Awards
  • Poetry Prize

Other Resources

  • ACP Online
  • Career Connection
  • ACP Advocate Blog
  • ACP Journal Wise

Follow Annals On

  • Twitter Link
  • Facebook Link
acp link acp
silverchair link silverchair

Copyright © 2018 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
INSTITUTIONAL SIGN IN
Open Athens|Shibboleth|Log In
Annals of Internal Medicine
PURCHASE OPTIONS
Buy This Article|Subscribe
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×